Table 2.

Experimental combination therapies with rituximab to address rituximab resistance and sensitivity

AgentMechanismTherapeutic partnersPatient populationClinical trial registrya
OblimersenBcl-2 antisense oligonucleotideRituximab, fludarabineCLLNCT00078234
RituximabNHLNCT00054639
NavitoclaxSmall-molecule Bcl-2 inhibitorFludarabine, cyclophosphamide, rituximabCLLNCT00868413
Bendamustine, rituximab
RituximabCD20-positive lymphoid malignanciesNCT00788684
Dose-intense rituximabCLLNCT01087151
ObatoclaxSmall-molecule Bcl-2 inhibitorFludarabine, rituximabCLLNCT00612612
Rituximab, bendamustineNHLNCT01238146
RituximabFLNCT00427856
CAL-101PI3K inhibitorRituximabCLL or SLLNCT01203930
Rituximab, bendamustine, ofatumumab, fludarabineNHL or CLLNCT01088048
EverolimusmTOR inhibitorRituximabDLBCLNCT00869999
Rituximab, chemotherapyDLBCLNCT01334502
EnzastaurinPKC inhibitorR-CHOPDLBCLNCT00451178
R-GEMOXDLBCLNCT00436280
DasatinibBCR/ABL and Src family tyrosine kinase inhibitorRituximabCLLNCT00949988
Rituximab, fludarabineCLL or SLLNCT01173769

Abbreviations: ABL, Abelson protein; BCR, breakpoint cluster region protein; SLL, small lymphocytic leukemia.